Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9138432 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Sep, 2025
(2 years from now) | |
US8586610 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Nov, 2027
(4 years from now) | |
US9157121 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Apr, 2030
(7 years from now) | |
US8652776 | VANDA PHARMS INC | Prediction of QT prolongation based on SNP genotype |
Aug, 2030
(7 years from now) | |
US8999638 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Oct, 2030
(7 years from now) | |
US9074255 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Dec, 2030
(7 years from now) | |
US9072742 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Jan, 2031
(7 years from now) | |
US9074256 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Feb, 2031
(8 years from now) | |
US9074254 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Dec, 2031
(8 years from now) |
Market Authorisation Date: 06 May, 2009
Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine; Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are poor metabolizers of cyp2d6; Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone; Dosage modification to reduce the risk associated with qt prolongation not induced by other drugs during treatment with iloperidone
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic